Chemring's chief executive designate Tom Newman has joined the defence technology group this week, ahead of taking over from Michael Ord in January, as the company approaches its financial year-end with a record order book.
Chemring Group (LSE:CHG) has begun a carefully staged Leadership transition, with incoming chief executive Tom Newman joining the Business on 5 October as chief executive designate. The FTSE 250 defence technology and energetics group is also nearing the close of its financial year at the end of October, and investors are watching for signs that solid Demand for munitions and countermeasures is translating into faster Earnings growth.
A planned succession
The company announced in late July that Michael Ord would retire after eight years at the helm. Mr Newman, who previously led Babcock International's Land and UK Aviation sector, a business with Revenue of around £1bn, will join the board and formally become group chief executive on 1 January 2027, the same day Mr Ord steps down. Chairman Tony Wood said the new chief executive has the skills to deliver solid growth and attractive returns.
There are other boardroom changes too. Group legal director and company secretary Sarah Ellard will step down from the board at the end of December and leave the company in February 2027. Recent filings have also shown changes in institutional shareholdings, including a notification on 6 October.
Order book strength meets execution challenges
Chemring's half-year results, published on 2 June, painted a mixed picture. Revenue for the six months to 30 April rose 7% to £237m, while the order book increased 8% to about £1.4bn. However, adjusted operating profit fell 8% to £24.5m, with delays to UK defence orders weighing on the period, and the shares fell around 5% on the day. The Interim Dividend was lifted 4% to 2.8p.
Management maintained its full-year outlook, noting that around 91% of expected 2026 revenue was already covered by the order book, compared with 85% a year earlier. That high level of visibility is important for a business whose earnings are often weighted towards the second half.
The group has also continued to win contracts. On 1 July it announced a single-supplier award from the US military for the Joint Biological Tactical Detection System, with an initial production contract worth $36.3m and an overall ceiling of $48.8m. The work will be carried out by its US sensors and electronics business in Charlotte, North Carolina. Further contract awards at its Alloy Surfaces countermeasures business followed later in June.
Defence spending tailwinds
The wider backdrop remains supportive. European governments have committed to sharply higher defence budgets, and NATO members have agreed to raise spending targets significantly over the coming decade. Replenishment of munitions stockpiles, particularly energetics and countermeasures used by armed forces, has been a recurring theme, and Chemring has been investing in additional Manufacturing capacity to meet demand.
At the same time, timing of government procurement decisions can create lumpiness in results, as the first half demonstrated. Execution on capacity expansion projects and the ability to convert the order book into profit will be central to the Investment case under new leadership.
Chemring's full-year results are typically published in December. For FTSE 250 investors, that report will provide the first detailed view of second-half delivery and may offer an early indication of Mr Newman's priorities as he prepares to take charge.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...